|
US9266891B2
(en)
|
2012-11-16 |
2016-02-23 |
Boehringer Ingelheim International Gmbh |
Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
|
|
MX2015007921A
(es)
|
2012-12-21 |
2016-03-03 |
Zenith Epigenetics Corp |
Compuestos heterociclicos novedosos como inhibidores de bromodominio.
|
|
CN105407888B
(zh)
|
2013-06-21 |
2019-05-21 |
齐尼思表观遗传学有限公司 |
新双环溴结构域抑制剂
|
|
WO2015004534A2
(en)
|
2013-06-21 |
2015-01-15 |
Zenith Epigenetics Corp. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
JP6542212B2
(ja)
|
2013-07-31 |
2019-07-10 |
ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． |
ブロモドメイン阻害剤としての新規キナゾリノン
|
|
EA035727B1
(ru)
|
2013-10-18 |
2020-07-31 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
|
JP6262363B2
(ja)
*
|
2013-11-26 |
2018-01-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
ブロモドメイン阻害剤としてのキノリン誘導体
|
|
US9920052B2
(en)
*
|
2013-12-09 |
2018-03-20 |
Ucb Biopharma Sprl |
Imidazopyridine derivatives as modulators of TNF activity
|
|
GB201321737D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CA2966303A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
CA2966298A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
GB201503720D0
(en)
*
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
|
JP7269731B2
(ja)
|
2015-03-18 |
2023-05-09 |
アルビナス・オペレーションズ・インコーポレイテッド |
標的タンパク質の分解向上のための化合物および方法
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
GB201504689D0
(en)
*
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201506660D0
(en)
*
|
2015-04-20 |
2015-06-03 |
Cellcentric Ltd |
Pharmaceutical compounds
|
|
EP3331905B1
(en)
|
2015-08-06 |
2022-10-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
US10501438B2
(en)
|
2015-08-11 |
2019-12-10 |
Neomed Institute |
Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
|
|
US10836742B2
(en)
|
2015-08-11 |
2020-11-17 |
Neomed Institute |
N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
|
|
CN114605387A
(zh)
|
2015-08-12 |
2022-06-10 |
埃皮吉纳提克斯股份有限公司 |
取代的苯并咪唑、它们的制备和它们作为药物的用途
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
US10501459B2
(en)
|
2015-10-21 |
2019-12-10 |
Neomed Institute |
Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
|
|
CA3007168A1
(en)
*
|
2015-12-14 |
2017-06-22 |
Zenith Epigenetics Ltd. |
1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
|
|
US10519151B2
(en)
|
2016-01-28 |
2019-12-31 |
Neomed Institute |
Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
|
|
CA3019342A1
(en)
|
2016-03-30 |
2017-10-05 |
Wisconsin Alumni Research Foundation |
Methods and compositions for modulating frataxin expression
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP4483875A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
GB201614939D0
(en)
*
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
GB201614940D0
(en)
*
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
WO2018106667A1
(en)
*
|
2016-12-05 |
2018-06-14 |
Microbiotix, Inc. |
Broad-spectrum inhibitors of filoviruses
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US11311609B2
(en)
|
2017-02-08 |
2022-04-26 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
US11759533B2
(en)
|
2017-03-29 |
2023-09-19 |
Wisconsin Alumni Research Foundation |
Methods and compositions for modulating gene expression
|
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
CN109111437B
(zh)
*
|
2017-06-22 |
2022-03-04 |
中国科学院广州生物医药与健康研究院 |
一种苯并[d]异恶唑类化合物及其制备方法和应用
|
|
CN109280046B
(zh)
*
|
2017-07-21 |
2021-02-02 |
浙江海正药业股份有限公司 |
苯并咪唑类衍生物及其制备方法及其在医药上的用途
|
|
WO2019028302A1
(en)
*
|
2017-08-04 |
2019-02-07 |
Bristol-Myers Squibb Company |
SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
|
|
EP3743067A1
(en)
*
|
2018-01-25 |
2020-12-02 |
Boehringer Ingelheim International GmbH |
Combination treatment of acute myeloid leukemia
|
|
EP3743066A4
(en)
|
2018-01-26 |
2021-09-08 |
Yale University |
IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
|
|
US10442799B1
(en)
|
2018-04-07 |
2019-10-15 |
Fuqiang Ruan |
Heterocyclic compounds and uses thereof
|
|
KR20210003804A
(ko)
|
2018-04-13 |
2021-01-12 |
아비나스 오퍼레이션스, 인코포레이티드 |
세레브론 리간드 및 이를 포함하는 2작용성 화합물
|
|
WO2020132561A1
(en)
|
2018-12-20 |
2020-06-25 |
C4 Therapeutics, Inc. |
Targeted protein degradation
|
|
JP2022053557A
(ja)
*
|
2019-02-08 |
2022-04-06 |
マルホ株式会社 |
ピリドン誘導体
|
|
EP3958867B1
(en)
*
|
2019-04-24 |
2024-06-26 |
Convergene Llc |
Small molecule bromodomain inhibitors and uses thereof
|
|
AU2020360170A1
(en)
|
2019-09-30 |
2022-05-19 |
Kyowa Kirin Co., Ltd. |
Bet degrader
|
|
CN118638043A
(zh)
|
2019-12-19 |
2024-09-13 |
阿尔维纳斯运营股份有限公司 |
用于雄激素受体的靶向降解的化合物和方法
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|